AbbVie
Institution - official statements with no named speaker · USA
Track record: No forecast checked yet (19 not due, 43 being checked).
63forecasts & commitments on the record
35%can be checked as stated
34average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 60, stated on authority 2, educated guess 1.
Kinds of claim: forecast 62, speculation 1. · Download this report card as a picture
In the nine words
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (63)
Additional data from this study, including results from a 36-week blinded extension period, are expected next year and will be used to support regulatory submissions for lutikizumab in HS in the second half of 2027.
The strategic relationship will pursue programs with first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise.
AbbVie is updating its adjusted diluted EPS guidance to include the impact of the proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in 2026, based upon an anticipated close in the third quarter of this year.
AbbVie expects an approval decision later this year, which would offer adult CD patients an additional option for induction of Skyrizi.
This North Chicago, Ill. facility is expected to be fully operational and serving patients by 2027.
Updates Outlook for Aesthetics to Deliver High Single-Digit Compound Annual Revenue Growth Rate from 2025 through 2029
Raises 2027 Combined Sales Outlook for Skyrizi and Rinvoq to More Than $31 Billion;
The company now expects a high single-digit compound annual revenue growth rate for aesthetics through 2029.
The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $31 billion, an increase of approximately $4 billion compared to previous guidance for combined revenues of more than $27 billion in 2027.
Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
Raises 2027 Combined Sales Outlook for Skyrizi and Rinvoq to More Than $27 Billion;
The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $27 billion, an increase of approximately $6 billion compared to previous guidance for combined revenues of more than $21 billion in 2027.
The company will issue its formal 2024 adjusted diluted EPS guidance range in conjunction with fourth quarter 2023 results.
As a result of this update, AbbVie does not expect adjusted diluted EPS for full year 2024 to be below $11.00 per share.
Results support Botox Cosmetic as a potential treatment option for moderate to severe platysma prominence and data will be included as part of an upcoming FDA regulatory submission expected near the end of the year.
"Looking forward, we have a solid foundation which will allow us to absorb the U.S. Humira loss of exclusivity, return to strong top-line growth in 2025 and drive top-tier financial performance over the long term."
Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its Humira-related patents in the U.S., which will begin on July 1, 2023.
AbbVie expects each asset to deliver risk-adjusted sales of greater than $7.5 billion in 2025.
"We are entering 2022 with significant momentum and expect our diverse set of growth assets, robust pipeline and excellent execution to deliver continued strong performance this year and over the long term."
The transaction is expected to close by the end of 2021, subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.
GEMINI 1 data, in combination with data from the GEMINI 2 study, formed the basis of the AGN-190584 New Drug Application (NDA) currently under review with the FDA, which the agency is expected to act on by the end of 2021.
The extension is for an additional three years, beginning in 2022, and AbbVie and Calico will each commit to contribute an additional $500 million.
If approved, AGN-190584 is expected to be the first eye drop to treat presbyopia and the FDA is expected to act on the NDA by the end of 2021.
“Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years – including five expected approvals in 2021."
AbbVie also outlined expectations for high-single digit annual growth for its aesthetics portfolio over the next decade, peak Vraylar (cariprazine) sales approaching $4 billion in current approved indications, peak Ubrelvy (ubrogepant) sales of greater than $1 billion and peak atogepant sales of greater than $1 billion.
•AbbVie announced that it will collaborate with 6 nonprofit partners as part of its $50 million investment to support health and education opportunity in underserved Black communities across the U.S. The partners include Direct Relief, University of Chicago Medicine's Urban Health Initiative, National Urban League, Year Up, United Negro College Fund (UNCF) and Providence St. Mel School.
Detailed data from both pivotal studies will be presented at an upcoming medical meeting and we expect to submit our regulatory applications for Skyrizi in PsA in the first half of this year.
The company expects a rapid return to strong top-line growth in 2025, with a high-single digit compound annual growth rate (CAGR) through the remainder of the decade.
AbbVie expects total company sales to decline in 2023, following the LOE, with modest top-line growth expected in 2024.
The company expects continued strong total company sales growth leading up to the U.S. Humira (adalimumab) loss of exclusivity (LOE) in 2023.
Additional details from the GEMINI 1 and GEMINI 2 studies will be presented at future medical meetings and will serve as the basis for a New Drug Application (NDA) submission to the FDA in the first half of 2021.
There will be no material change in the operational strategy or current management of AbbVie during the year ending December 31, 2019 other than those already announced;
Executed licensing and partnership collaboration transaction impacts and transactions expected to be executed in the next quarter are included.
AbbVie and Allergan continue to expect to close the transaction in early 2020.
AbbVie Expects to Close the Transaction in Early 2020
The U.S. license for BI will begin on July 1, 2023.
AbbVie expects to deliver adjusted diluted EPS for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point.
The license period will begin on November 20, 2023 in the U.S. for both Momenta and Pfizer, and will not be accelerated by the entry of companies who have already taken a license.
The license period will begin on September 30, 2023 in the U.S. for both Sandoz and Fresenius Kabi, and will not be accelerated by the entry of companies who have already taken a license.
Data from the Phase 3 program will support regulatory submission for elagolix in uterine fibroids, anticipated in 2019.
Data from the pivotal Phase 3 studies will be presented at a medical conference later this year and the ELARIS UF-EXTEND Phase 3 study data will be presented at a future medical conference.
“We’re particularly pleased with our progress in building a leading hematologic oncology franchise, which is now delivering revenue in excess of $1 billion per quarter and is poised for continued strong growth next year and beyond.”
AbbVie continues to anticipate the company’s adjusted effective tax rate to increase to 13 percent over the next five years as a result of increased domestic income and investment.
Mylan’s U.S. license will begin on July 31, 2023.
Under the terms of the settlement agreements, AbbVie will grant to Samsung Bioepis a non-exclusive license to AbbVie's intellectual property relating to HUMIRA beginning on certain dates in certain countries in which AbbVie has intellectual property, including on June 30, 2023 in the U.S. and on October 16, 2018 in most countries in the European Union.
Data from both pivotal studies will support regulatory submissions for elagolix in uterine fibroids and will be presented at a medical conference later this year.
Ongoing Phase 3 studies, MERU and TAHOE, will continue to investigate Rova-T in first- and second-line SCLC, with readouts expected in the 2020 timeframe.
The Phase 3 program for upadacitinib in atopic dermatitis is expected to begin later this year.
The company expects to report data from an additional pivotal study (SELECT-EARLY) and submit regulatory applications later this year, with commercialization anticipated in 2019.
AbbVie anticipates the company’s adjusted effective tax rate to increase to 13 percent over the next five years as a result of increased domestic income and investment.
Showing the newest 50 - the ledger has all 63.